U.S. License Holder:
Provention Bio Inc.
Date of License:
November-17-2022
Last Update:
Dec-15-2024
FDA-Approved Indications
TZIELD (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.